Munshi N C, Avet-Loiseau H. Genomics in multiple myeloma[J]. Clin Cancer Res, 2011, 17(6): 1234-1242. [2]Morishita H, Yagi T. Protocadherin family: diversity, structure, and function[J]. Curr Opin Cell Biol, 2007, 19(5): 584-592. [3]Kim S Y, Yasuda S, Tanaka H, et al. Non-clustered protocadherin[J]. Cell Adh Migr, 2011, 5(2): 97-105. [4]Nakao S, Platek A, Hirano S, et al. Contact-dependent promotion of cell migration by the OL-protocadherin-Nap1 interaction[J]. J Cell Biol, 2008, 182(2): 395-410. [5]Bertrand K C, Mack S C, Northcott P A, et al. PCDH10 is a candidate tumour suppressor gene in medulloblastoma[J]. Childs Nerv Syst, 2011, 27(8): 1243-1249. [6]Li Z, Li W, Xie J, et al. Epigenetic inactivation of PCDH10 in human prostate cancer cell lines[J]. Cell Biol Int, 2011, 35(7): 671-676. [7]Li Y, Yang Z S, Song J J, et al. Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma[J]. Int J Mol Med, 2012, 29(4): 704-710. [8]Lin Y L, Li Z G, He Z K, et al. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer[J]. J Int Med Res, 2012, 40(6): 2117-2123. [9]Narayan G, Scotto L, Neelakantan V, et al. Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer[J]. Genes Chromosomes Cancer, 2009, 48(11): 983-992. [10]Yu B, Yang H, Zhang C, et al. High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers[J]. Neoplasma, 2009, 57(3): 247-252. [11]Narayan G, Freddy A J, Xie D, et al. Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance[J]. Genes Chromosomes Cancer, 2011, 50(12): 1043-1053. [12]李颖, 陈建斌, 宋君君, 等. 甲基化修饰致PCDH10基因在多发性骨髓瘤中沉默[J]. 第三军医大学学报, 2012, 34(9)：817-820. [13]Li Z, Chim J C, Yang M, et al. Role of PCDH10 and its hypermethylation in human gastric cancer[J]. Biochim Biophys Acta, 2012, 1823(2): 298-305. [14]Ying J, Li H, Seng T J, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation[J]. Oncogene, 2006, 25(7): 1070-1080. [15]Tang X, Yin X, Xiang T, et al. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer[J]. Cancer Biomark, 2012, 12(1): 11-19. [16]Echizen K, Nakada M, Hayashi T, et al. PCDH10 is required for the tumorigenicity of glioblastoma cells[J]. Biochem Biophys Res Commun, 2014, 444(1): 13-18. [17]李珍, 陈建斌, 彭曦, 等. PCDH10基因促进多发性骨髓瘤细胞凋亡及机制研究[J]. 第三军医大学学报, 2014, 36(5): 437-441. [18]Que W, Chen J, Chuang M, et al. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity[J]. APMIS, 2012, 120(3): 195-203. [19]Kang M H, Oh S C, Lee H J, et al. Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression[J]. Exp Cell Res, 2011, 317(12): 1746-1762. [20]Ho Y P, Kuo C W, Hsu Y T, et al. beta-Actin is a downstream effector of the PI3K/AKT signaling pathway in myeloma cells[J]. Mol Cell Biochem, 2011, 348(1/2): 129-139. [21]Wang R C, Wei Y, An Z, et al. Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation[J]. Science, 2012, 338(6109): 956-959. [22]Sun C Y, Hu Y, Huang J, et al. Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling[J]. Tumor Biol, 2010, 31(2): 121-128.
[2]
李佳丽,刘耀,曾东风,等.硼替佐米联合地塞米松和沙利度胺治疗多发性骨髓瘤的临床研究[J].第三军医大学学报,2012,34(24):2515. Li Jiali,Liu Yao,Zeng Dongfeng,et al.Bortezomib combined with dexamethasone and thalidomide in treatment of multiple myeloma: report of 58 cases[J].J Third Mil Med Univ,2012,34(20):2515. [2]段海玲,熊玮,杨和平,等.误诊为肺癌骨转移的多发性骨髓瘤1例[J].第三军医大学学报,2008,30(10):931. [3]杨再林,张勇,张伶,等.硼替佐米联合化疗对多发性骨髓瘤的疗效与相关血液学指标分析[J].第三军医大学学报,2010,32(09):975. Yang Zailin,Zhang Yong,Zhang Ling,et al.Effect of bortezomib in combination with chemotherapy on multiple myeloma and change in its hematological indexes[J].J Third Mil Med Univ,2010,32(20):975. [4]张超,陈晓红.Syndecan-1在多发性骨髓瘤发病中作用的研究进展[J].第三军医大学学报,2005,27(18):1891. [5]谢家印,王东,李梦侠,等.APE1/Ref-1 siRNA抑制多发性骨髓瘤骨髓基质细胞IL-6及IL-8分泌的体外研究[J].第三军医大学学报,2009,31(19):1850. XIE Jia-yin,WANG Dong,LI Meng-xia,et al.APE1/Ref-1 siRNA inhibits IL-6 and IL-8 secretion by cultured bone marrow stromal cells isolated from multiple myeloma patients[J].J Third Mil Med Univ,2009,31(20):1850. [6]谢家印,杜佳,李梦侠,等.RNA干扰骨髓基质细胞和/或骨髓瘤细胞APE1表达对共培养骨髓瘤细胞增殖及凋亡的影响[J].第三军医大学学报,2011,33(10):1008. Xie Jiayin,Du Jia,Li Mengxia,et al.Effects of RNA interference inhibiting APE1 expression in bone marrow stromal cells and/or U266 cells on proliferation and apoptosis of co-cultured U266[J].J Third Mil Med Univ,2011,33(20):1008. [7]高力,张曦,高蕾,等.不同来源基质细胞对骨髓瘤KM3细胞增殖和凋亡的影响[J].第三军医大学学报,2009,31(10):879. GAO Li,ZHANG Xi,GAO Lei,et al.Effect of stromal cells derived from different origins on proliferation and apoptosis of KM3 cells[J].J Third Mil Med Univ,2009,31(20):879. [8]李颖,陈建斌,宋君君,等.甲基化修饰致PCDH10基因在多发性骨髓瘤中沉默[J].第三军医大学学报,2012,34(09):817. Li Ying,Chen Jianbin,Song Junjun,et al.Methylation induces protocadherin-10 silence in multiple myeloma[J].J Third Mil Med Univ,2012,34(20):817. [9]侯慧明,张红宾,刘林.IgG型多发性骨髓瘤自体造血干细胞移植后复发合并急性淋巴细胞白血病1例[J].第三军医大学学报,2013,35(13):1361. [10]张亮,杜佳,周立为,等.依布硒诱导多发性骨髓瘤细胞凋亡及其机制的研究[J].第三军医大学学报,2014,36(02):110. Zhang Liang,Du Jia,Zhou Liwei,et al.Ebselen induces apoptosis in human multiple myeloma cell line U226[J].J Third Mil Med Univ,2014,36(20):110.
